Ben Saylor

Phase 1/2 data presented at the 2021 ASCO Annual Meeting for the novel PSMA-targeting agent HPN424 show tumor responses in patients with pretreated metastatic castration-resistant prostate cancer.

The safety and efficacy of experimental combinations of investigational agents are being analyzed as treatment for advanced clear cell renal cell carcinoma as part of a phase 1b/2 umbrella platform study.

Compared with androgen-deprivation therapy alone, patients with metastatic castration-sensitive prostate cancer had better outcomes when apalutamide was added to systemic therapy.

Patients who underwent pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.

This study found that radiation therapy may provide some benefit for patients with high-risk non–muscle invasive bladder cancer, though the quality of evidence in this current setting is low.

Durvalumab, with or without tremelimumab, failed to meet its primary end point of overall survival in patients with metastatic urothelial cancer.

The combination use of nivolumab plus ipilimumab, compared with sunitinib, continued to show benefit during a 4-year follow-up in patients with advanced renal cell carcinoma.